Visual Disturbance and Elevated Glutamic Acid Decarboxylase Antibody Levels as Manifestations of Central Nervous System Lymphoma.
1/5 보강
Various neurologic manifestations are observed in the course of hematologic malignancies.
APA
Tan S, Lin PT, et al. (2026). Visual Disturbance and Elevated Glutamic Acid Decarboxylase Antibody Levels as Manifestations of Central Nervous System Lymphoma.. Neurology India, 74(2), 287-290. https://doi.org/10.4103/neuroindia.NI_855_20
MLA
Tan S, et al.. "Visual Disturbance and Elevated Glutamic Acid Decarboxylase Antibody Levels as Manifestations of Central Nervous System Lymphoma.." Neurology India, vol. 74, no. 2, 2026, pp. 287-290.
PMID
41817073
Abstract
Various neurologic manifestations are observed in the course of hematologic malignancies. Clinical neurologic symptoms and manifestations of malignancies may result from the malignancy itself, inflammatory responses, or paraneoplastic syndromes. Therefore, differential diagnosis on the basis of clinical presentation is challenging. This is the first study to report a patient with central nervous system lymphoma and elevated glutamic acid decarboxylase antibody levels who presented with uveitis masquerade syndrome (UMS), followed by progressive consciousness change, mimicking autoimmune encephalitis.
🏷️ 키워드 / MeSH
같은 제1저자의 인용 많은 논문 (5)
- Dietary advice alone or with oral nutritional supplements after hospital discharge in colorectal cancer surgery patients: Five year follow-up of a randomized controlled trial.
- Ceritinib-ibuprofen synergistic hepatotoxicity: Insights from real-world data and liver organoid models.
- Primary sinonasal DLBCL: High prevalence of MCD subtype and CNS risk.
- HOXC8-activated TRIM22/NF-κB pathway promotes stemness in colorectal cancer.
- Cardiovascular risk in cancer patients treated with immune checkpoint inhibitors: challenges and future directions.